Abstract：Objective To investigate the clinical significance of pulse high-volume hemofiltration (PHVHF) on expressions of Toll-like receptor (TLR) 2 and TLR4 mRNA in peripheral blood mononuclear cells (PBMCs) in patients with severe sepsis． Methods Forty patients with severe sepsis were divided into conventional treatment group (n=20) and PHVHF group (n=20) according to random number table. Another fifteen healthy volunteers served as controls. TLR2 and TLR4 mRNA expressions in PBMCs were detected using RT-PCR and plasma concentrations of TNF-α and IL-6 were measured using ELISA method before therapy and at 24 h, 48 h and 72 h after therapy. Vital signs, BIL, Cr, BUN, Lac, PaO2/FiO2, acute physiology, chronic health evaluation Ⅱ (APPACHEⅡ), sequential organ failure assessment (SOFA) and prognosis were compared among the groups． Besides, complications associated with PHVHF therapy were monitored. Results Expressions of TLR2 and TLR4 mRNA in PBMCs and concentrations of TNF-α and IL-6 were significantly higher in patients with severe sepsis than in the controls (P<0.01). At 72 hours after therapy, PHVHF group showed significantly lower concentrations of TNF-α and IL-6 than those before therapy (P<0.01) as well as significantly lower expressions of TLR2 and TLR4 mRNA in PBMCs than those in conventional treatment group (P<0.01). However, no significant decline in the levels of TNF-α and IL-6 and the expressions of TLR2 and TLR4 mRNA in PBMCs were shown in conventional treatment group after therapy. At 72 hours after therapy, PHVHF group showed significant increases of MAP and PaO2/FiO2 and significant decreases of Cr, BUN, Lac, APACHEⅡ and SOFA as compared to those before therapy (P<0.05). Moreover, the differences of MAP, PaO2/FiO2, Cr, BUN, Lac, APACHEⅡ and SOFA were statistically significant between and conventional treatment group at 72 hours after therapy (P<0.05). Conclusion PHVHF achieves a reduced systemic inflammatory response, improved major organ functions, shortened length of stay in ICU and down-regulated TLR2 and TLR4 expressions in PBMCs that may be a novel mechanism of PHVHF in treatment of severe sepsis.
QIU Ze-liang,ZHANG Ning,XU Jun-long et al. Effect of pulse high-volume hemofiltration on Toll-like receptor expression and organ function in patients with severe sepsis[J]. CHINESE JOURNAL OF TRAUMA, 2013, 29(8): 785-789.
［2］Brendolan A, D’Intini V, Ricci Z, et al. Pulse high volume hemofiltration. Int J Artif Organs, 2004, 27(5):398-403.
［3］Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med， 2003, 29(4):530-538.
［4］Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med, 2008, 36(1):296-327.
［5］Seldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol, 1953, 39(5):368-376.
［6］Vincent JL, Atalan HK. Epidemiology of severe sepsis in the intensive care unit. Br J Hosp Med (Lond)， 2008, 69(8):442-443.
［7］Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med， 2002, 30(1):100-106.
［8］Grootendorst AF, van Bommel EF, van Leengoed LA, et al. High volume hemofiltration improves hemodynamics and survival of pigs exposed to gut ischemia and reperfusion. Shock， 1994, 2(1):72-78.
［9］Honoré PM, Joannes-Boyau O, Gressens B. Blood and plasma treatments:high-volume hemofiltration-a global view. Contrib Nephrol， 2007， 156:371-386.
［11］Ratanarat R, Brendolan A, Ricci Z, et al. Pulse high-volume hemofiltration in critically ill patients: a new approach for patients with septic shock. Semin Dial， 2006, 19(1):69-74.
［12］Ratanarat R, Brendolan A, Piccinni P, et al. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care, 2005, 9(4):R294-R302.
［14］Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol， 2010, 11 (5):373-384.
［15］Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity， 2011, 34(5):637-650.
［16］Lien E, Sellati TJ, Yoshimura A, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem, 1999, 274(47):33419-33425.
